Kailera Therapeutics
Kailera Therapeutics is a clinical-stage biopharmaceutical company advancing a diversified pipeline of next-generation GLP-1 therapies for obesity, including lead injectable asset ribupatide (KAI-9531), an oral formulation, and KAI-7535, an oral small molecule GLP-1 receptor agonist. The pipeline was in-licensed through a strategic collaboration with Jiangsu Hengrui Pharmaceuticals. Kailera launched in October 2024 with a $400 million Series A co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments, followed by a $600 million Series B led by Bain Capital Private Equity in October 2025, and completed a roughly $625 million IPO in April 2026.
Company Facts
- Headquarters: Waltham, United States
- Founded: 2024
- Type: public
- Website: https://www.kailera.com
- Industries: Biotechnology, Pharmaceuticals, Obesity Treatment, Clinical Stage
Key People at Kailera Therapeutics
- Chris Hite — Independent Board Member and Audit Committee Chair, Kailera Therapeutics
- John F. Milligan — Board Chair, Kailera Therapeutics
- Ron Renaud — Chief Executive Officer, Kailera Therapeutics